<4384> Raksul 1108 -95.

Significantly declined. The company announced its financial results for the fiscal year ending July 2024 the previous day. Operating profit increased by 42.9% compared to the previous year to 2.52 billion yen, surpassing the previous estimate of 2.3 billion yen. The forecast for the fiscal year ending July 2025 is in the range of 3.2-3.7 billion yen, with a midpoint of 3.45 billion yen, an increase of 36.7% from the previous year. The planned annual dividend is 2.3 yen, an increase of 0.6 yen compared to the previous year. The guidance for this fiscal year is somewhat negative compared to the consensus, but the current stock price is in a high range, and there is a sense of expectation or exhaustion as well.

<4880> CellSource 1354 -27.

Significantly declined. The company announced its third quarter financial results the previous day, with cumulative operating profit decreasing by 62.8% compared to the same period last year to 0.39 billion yen. As a result, the full-year forecast was revised downward from the previous 1 billion yen to 0.42 billion yen. It seems that the number of orders from self-pay medical institutions specializing in volatile services such as adipose-derived stem cells, synovial-derived stem cells, and blood-derived processing services is expected to decrease more than expected. The negative view of a performance deterioration beyond expectations is strengthening.

<6619> WSCOPE 371 -30.

Significantly declined. The company announced its interim financial results the previous day, with operating income decreasing by 60.8% compared to the same period last year to 1.07 billion yen, falling below the previous estimate of 1.4 billion yen. The increase in transportation costs beyond expectations was due to the disruption of maritime transportation in the Middle East, the rise in sea freight rates for Hungary, and the switch to air freight for some product shipments. In addition, there is a possibility that the consolidated subsidiary will become an equity method company, so the full-year forecast has been withdrawn and is undecided. The combination of lower-than-expected results for the first half of the year and increased uncertainty.

<4194> Visional 8640 -520.

Significantly declined. The company announced its financial results for the fiscal year ending July 2024 the previous day, with operating profit increasing by 34.9% compared to the previous year to 17.8 billion yen, slightly exceeding the upward revision level announced at the third quarter financial results announcement. On the other hand, the forecast for the fiscal year ending July 2025 is 19.15 billion yen, an increase of 7.4% from the previous year, with the profit growth rate slowing down. The consensus is expected to be about 1 billion yen lower. BizReach is expected to have high sales growth of 15%, but it is expected that the profit margin will decrease due to increased advertising and publicity expenses, increased personnel expenses, and increased investment in other businesses.

<2929> PharmaF 888 -70. Significant decline. The company announced its financial results for the fiscal year ending July 2024. Operating profit increased by 41.6% compared to the previous year, reaching the level of significant upward revision on July 25. On the other hand, the forecast for the fiscal year ending July 2025 is a significant decline in profit of 60.9% to 2 billion yen, which could be a selling point. The company also plans to start a challenging investment of 30 billion yen over the next five years. For the fiscal year ending July 2025, the company plans to increase investment in Expo projects, egg membrane business, and advertising by more than 3 billion yen compared to the previous year.

<3475> GoodcomA 786 -65. Significant decline. The company announced its third-quarter financial results, with cumulative operating profit increasing by 84.4% compared to the same period last year, reversing the 32.2% decline in the first half and turning into a significant increase in profit. However, the progress rate towards the unchanged full-year plan of 5.34 billion yen remains at 53.6%, and concerns about not achieving the target have not been completely eliminated, leading to a feeling of exhaustion. The announcement of a share buyback of up to 0.9 million shares, equivalent to 3.12% of the issued shares, and a limit of 765 million yen also had limited positive impact.

<7012> Kawasaki Heavy 4918 +333. Significant increase. Goldman Sachs Securities has started coverage with a 'buy' rating and a target stock price of 7000 yen. Although the contribution of the aviation and defense sector, which is the source of profit growth, is comparable to that of the two major competitors, the underperformance in stock price evaluation is notable. It is said that the company is underperforming the two competitors by 72% year-to-date. Based on the reliability of the relative profit outlook and the undervaluation reflected in the stock price evaluation, it seems to be in a favorable position for preference.

<3539> JMHD 3245 +190. Significant increase. The company announced its financial results for the fiscal year ending July 2024, with operating profit increasing by 26.3% compared to the previous year and reaching the level of the upward revision in July. The annual dividend is planned to be raised by 2 yen to 42 yen. For the fiscal year ending July 2025, the forecast is an operating profit increase of 8.2% to 9.9 billion yen, and the annual dividend is planned to be increased by 2 yen to 44 yen. In addition, the company announced a share buyback through off-market trading, with a maximum of 1.4 million shares and 4.277 billion yen, in response to the significant increase in shareholding by major shareholders.

<2929> PharmaF 888 -70. Significant decline.

<3475> GoodcomA 786 -65. Significant decline.

<7012> Kawasaki Heavy 4918 +333. Significant increase.

<3539> JMHD 3245 +190. Significant increase.

<7095> MacbeeP 3165 +150

Significant increase. The company announced its first quarter financial results the previous day, with operating profit at 1.15 billion yen, a 14.8% increase compared to the same period last year. Although there were no surprises compared to the company's annual plan, it achieved double-digit revenue and profit growth. In addition, the annual dividend, which was previously undecided, will be 36 yen, an increase of 22 yen compared to the previous period. Furthermore, the company announced a share buyback of up to 0.65 million shares and 1.65 billion yen, which is believed to be in response to some major shareholders selling their shares.

<6184> Kamakura Shosho 481 +80

Hitting the daily limit. The company announced its first half financial results the previous day, with operating profit at 0.37 billion yen, a 15.2% increase compared to the same period last year, and an increase in profit growth rate from the 4.9% increase in the first quarter. The company has decided on a shareholder return policy for the three-year medium-term plan, transitioning from its previous stable dividend policy. As a limited measure during the medium-term plan period, the company has decided to maintain a dividend payout ratio of 100% or a low of 20 yen per share. As a result, the annual dividend for the January 2025 period will be increased by 16 yen to 20 yen compared to the previous period.